Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 7/20 | 0.69 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.69 |
| ▸ | GRIA3 | P42263 | 7/20 | 0.69 |
| ▸ | GRIA4 | P48058 | 7/20 | 0.69 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784577 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL29798454 | 0.78 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL678318 | 0.78 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6785878 | 0.76 | GRIA1 (0.88) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6780551 | 0.73 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7103934 | 0.72 | GRIA1 (0.81) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL7959740 | 0.72 | GRIA1 (0.87) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8474001 | 0.71 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8351148 | 0.69 | GRIA1 (0.59) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL8477906 | 0.69 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5968928-A | Excitatory amino acid antagonists: fused-azacyclic quinoxalinediones and immunoassays thereof | WARNER-LAMBERT COMPANY (US) | 1999-10-19 | — | — | US | claimed |
| WO-1999025327-A2 | SMALL MOLECULE INTERVENTION IN HIV-1 REPLICATION | WARNER-LAMBERT COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| US-8603980-B2 | Glutamate receptor antagonists and methods of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| EP-2150248-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | The Johns Hopkins University (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008088820-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-5968928-A | Excitatory amino acid antagonists: fused-azacyclic quinoxalinediones and immunoassays thereof | WARNER-LAMBERT COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1999025327-A2 | SMALL MOLECULE INTERVENTION IN HIV-1 REPLICATION | WARNER-LAMBERT COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.